GlaxoSmithKline (GSK) has formed a collaboration with Fimbrion Therapeutics, a start-up biotechnology company based in St. Louis, Missouri, to develop a small-molecule drug for the treatment and prevention of urinary tract infections. The agreement creates a joint project between Fimbrion and the Discovery Partnerships with Academia team at GSK focused on the preclinical development of a class of mannose-containing small-molecule compounds called mannosides.

Mannosides represent a potential treatment for bacterial infections by preventing bacteria from adhering to the bladder and allowing the body to eliminate the infection, according to Fimbrion. Fimbrion’s initial focus will be to develop an orally active formulation.

Source: Fimbrion Therapeutics